Juggling With Knives: Profits, protection and planning for volatility in stocks, bonds, real estate, and real life.
This website is based on my book, Juggling with Knives. Both the book and website are about volatility in everything from stocks and bonds to real estate, and real life topics such as jobs and education.
This website keeps the content of the book fresh and the advice and strategies up to date. If you’ve purchased the book, you’ve earned a one-year free subscription. Use the Coupon Code in the book to start your one-year FREE SUBSCRIPTION when you Subscribe on this website.
I run two other investing websites, Jubak Picks and Jubak Asset Management. So how does Juggling With Knives fit in that group? With a subscription at $79 a year you get everything that appears on my free JubakPicks.com website (1 to 2 posts a day plus buys/sells/updates on three portfolios) plus an additional 1 or 2 posts a day, including a special post on volatility on most days, plus access to my new Volatility Portfolio. My premium site, Jubak Asset Management, JubakAM.com to its friends, offers for $199 a year everything on Jubak Picks, plus everything on Juggling With Knives, plus exclusive posts that include Sector Monday, Friday Trick or Trend, Saturday Night Quarterback, and my daily Notes You Can Use Mini Blog. Oh, and videos where my smiling face explains the markets. If you’d like to step up to a JubakAm.com subscription click here. (You’ll get full credit for what you paid to subscribe to Juggling With Knives.)[stock-ticker name=”Ticker”]
If you spend a significant part of your day staring at your computer to watch the markets, you know that, perplexingly, the traditional safe havens for mitigating portfolio risk haven’t been working very well. Now Goldman Sachs has put its computers and data crunchers to work and has reached the same conclusion as the anecdotal evidence suggested. Goldman has tagged this a period of “diversification desperation.”read more
It’s only March but I’m rethinking my take on 2018.When the calendar pages turned over into 2018, my take on the year was that for stocks the first half would be much like 2017: Despite rising interest rates from the Federal Reserve, there was enough earnings growth to move stocks up even from near record highs. The bond market would be more problematic with those interest rate increases keeping downward pressure on bond prices and upward pressure on bond yields. With inflation still relatively quiescent, though, the downward trend in bond prices would be relatively gradual. It was the second half of the year that investors had to worry about, I thought then.read more
The market has finally (and probably only momentarily) stabilized enough for me to rebalance my Volatility Portfolio. My intention was to rebalance at the end of January but then stuff happened. You know 9% drop in the Standard & Poor’s 500, huge spike in volatility (as measured by the CBOE S&P Volatility Index (VIX) anyway), correlations shifting all over the place. But after the portfolio’s 53% gain in 2017 and with the changes in the market’s risk profile that are emerging, this portfolio badly needs a rebalance. And here it is. The portfolio is going into this rebalancing with 12 positions. It’s going to come out with 12 positions, although not the same 12 positions and not with the same weights for each positionread more
When I started my Volatility Portfolio back in January 2017, I really didn’t have much more in mind than a conviction that in this market traders and investors and traders could score market beating returns from taking advantage of market and economic volatility. I didn’t narrow my approach to volatility to one or two aspects or markets, but instead followed a wide menu approach to volatility as a characteristic stretching across markets from real estate to bonds to education to stocks. That menu as based on the research I’d done for my February 2016 book Juggling with Knives: Smart Investing in the Coming Age of Volatility. Certainly the return on this portfolio for its first year of operation confirm this wide-menu approach. The portfolio showed a total return of 53.06%–assuming equal initial weightings in each position–as of December 31, 2017. That qualifies, I’d say, as beating the market in 2017. The total return on the Standard & Poor’s 500 stock index was 21.64% in 2017. But in that first year of operation I found a more focused goal for the Volatility Portfolio too.read more
Back in October 2017 I set up a very simple portfolio of 5 ETFs with the goal of beating the performance of a Standard & Poor’s 500 ETF (so that’s the benchmark) with less risk (because of the added diversification.) I said that I would rebalance this portfolio as needed–or on a six month schedule (which ever came first.) But that this would be a relatively passive portfolio of passive ETFs–but with some active management thrown in by way of those shifting allocations. Well, the portfolio certainly isn’t six months old, but we have flipped the calendar page into 2018 so I’m going to do the first performance report now and at the same time do an initial rebalancing of assets.read more
2017 left investors with a huge challenge as we all move into 2018. After a 21.6% return on the Standard & Poor’s 500 stocks in 2017, do we let the money ride for 2018 or move it into other assets? Some stocks had almost unbelievable years in 2017. Amazon (AMZN) was up 56% for the year an Facebook (FB) climbed 53%. But those gains were left in the dust by the 96% gain on Alibaba (BABA) and the 115% racked up by Tencent Holdings (TCEHY). And even stocks seem to be standing still in comparison to biotech such as Madrigal Pharmaceuticals (MDGL), up 510% in 2017 or Sangamo Therapeutics (SGMO) ahead by 466%. For 2018 should you leave your money in those big winners from last year? Take some of it off the table and put it into laggards? Move some of it to cash?read more
Two robotics and automation ETFs–if you’d prefer that route to buying Fanuc and Nidec in my 50 Stocks Portfolio
Back on July 11 I argued that for investors at least it was better to buy robotics stocks than to try to fight the global trend toward automation. I added two robotics stocks, both Japanese companies, to my long-term 50 Stocks Portfolio that day. Since then Fanuc (FANUY) is up 27.92% and Nidec (NJDCY) is ahead 34.23%. But the evidence is that a lot of investors want to own a piece of the sector but would be prefer to use an ETF to give them broad exposure to the sector. Launched in 2013, Global Robotics and Automation Index ETF (ROBO) how has nearly $2 billion in assets under management. Global X Robotics and Artificial Intelligence Thematic (BOTZ) moved above $1 billion in assets back in August.read more
Pick the biggest stock market turkey. Win $1000. By and large, 2017 has been a great year for stocks. Amazon (AMZN), for example, is up 50.68% for 2017 as of the close on November 17. Casting our nets wider, the Standard & Poor’s 500 stock index is ahead 14.22%But that doesn’t mean every stock has gone up this year. Bed Bath & Beyond (BBBY), to mention just one retailer, is down 49.01% in 2017. We’re entering the strong end of year season for stocks. From 1928 to 2017 U.S.stocks have climbed 72% of the time in December, the best performance during any single month. But there are signs of risk at the edges of the market. Investors have been rotating out of wobbling sectors and into sectors with a little momentum at the drop of a crystal ball. So put on your wizard’s hat and pick the biggest turkey for the three months beginning on December 1 and ending on March 1. Pick the biggest stock market turkey and Jubak Picks/Juggling with Knives/Jubak Asset Management–in other words, me–will award you $1,000 in cashread more
Shares of Nektar Therapeutics (NKTR) are up another 16% this morning to $37.89 as of noon New York time on data presented this weekend at the annual meeting of the Society for Immunotherapy of Cancer from an early trial of Nektar’s NKTR-214. The data looked at the efficacy and safety of NKTR-214 in combination with Bristol-Myers Squibb’s (BMY) Opdivo. Opdivos a PD-1 immune checkpoint inhibitor designed to overcome immune suppression. NKTR-214 is a immuno-stimulatory drug candidate designed to expand and activate specific cancer-fighting T cells and natural killer cells directly in the tumor.read more
My fifth pick for my new Perfect 5 ETF portfolio: iShares Emerging Markets (EEM) but with a caveat or two
I’m illustrating this post on adding the iShares MSCI Emerging Markets ETF (EEM) with a Chinese flag because that’s what you get (China) with this “diversified” emerging markets ETF. 10 of the first 20 stocks, ranked by percentage of the portfolio each holding makes up, is a Chinese company.read more